<DOC>
	<DOC>NCT01422265</DOC>
	<brief_summary>This multicenter, observational, prospective study will include approximately 20 US-based centers, and approximately 142 patients diagnosed with epithelial ovarian cancer, primary peritoneal carcinoma or fallopian tube carcinoma, whose disease has recurred &gt; 6 months after first-line platinum-based chemotherapy (first recurrence). Patients who have completed second-line chemotherapy and are currently in observation or undergoing bevacizumab maintenance treatment will be eligible to participate in the study.</brief_summary>
	<brief_title>Patient Reported Symptoms in Ovarian Cancer (PRECISION)</brief_title>
	<detailed_description />
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<criteria>Histologically documented ovarian cancer, primary peritoneal carcinoma or fallopian tube carcinoma that has recurred &gt; 6 months after platinumbased chemotherapy This must be the first recurrence of the epithelial ovarian cancer, primary peritoneal carcinoma or fallopian tube carcinoma Are at least two weeks but no more than 3 months after the completion of secondline cytotoxic chemotherapy Are currently under observation or being treated with bevacizumab as a secondline maintenance therapy Have a valid email address and access to the internet Provide voluntary written informed consent Speak and read English fluently Current participation in a blinded clinical trial for ovarian cancer treatment. (Participation in a trial involving only supportive care medicines and/or growth factors is acceptable) Another primary diagnosis of cancer in a different site</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>